Clinical Trials
22 trialsNCT07288359 2026-05-27
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT05768139 2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT07596212 2026-05-19
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
Phase 1/2 Not yet recruiting
NCT07570966 2026-05-06
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Not yet recruiting
NCT01872260 2026-04-01
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis
Phase 1/2 Active not recruiting
NCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT02520063 2026-02-06
Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT06974929 2025-12-30
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT02562118 2025-09-25
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT06555068 2025-06-22
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT03481998 2023-11-21
A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT03054363 2023-11-13
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
University of Colorado, Denver
Phase 1/2 Completed
NCT00634634 2023-11-09
Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Rutgers, The State University of New Jersey
Phase 1/2 Completed
NCT03772353 2023-03-07
PLEASURABLE
Fudan University
Phase 1/2 Unknown
NCT01791985 2022-08-22
RADICAL
Imperial College London
Phase 1/2 Completed
NCT03913234 2022-05-10
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
Yonsei University
Phase 1/2 Unknown
NCT00290745 2020-12-04
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
University of California, San Francisco
Phase 1/2 Completed
NCT04488107 2020-07-27
Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c
Ahon Pharmaceutical Co., Ltd.
Phase 1/2 Unknown
NCT01484041 2018-02-09
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Georgetown University
Phase 1/2 Terminated
NCT01105312 2017-06-27
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT01082068 2016-06-03
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Sanofi
Phase 1/2 Completed